Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Boehringer Ingelheim
Study ID
NCT01867307
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

Study Details

Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls

Key Dates

Start date
Jun 30, 2013
Status verified
Mar 2017
Primary completion
Oct 31, 2015
Completion
Oct 31, 2015

Study Design

Enrollment
39 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Healthy Controls
    healthy controls
  • Experimental: Patients
    patients with type 2 diabetes mellitus

Primary Outcome Measure

Change From Baseline of Renal Tubular Maximum Reabsorptive Capacity for Glucose (TmG) at End of Empagliflozin Treatment (Day 14) [ Time Frame: Baseline and Day 14 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Boehringer Ingelheim Investigational SiteSan AntonioTexas--

Find similar trials in San Antonio, TX

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Boehringer Ingelheim Investigational Site· San Antonio, TX

Related Studies